Actively Recruiting

Phase 2
Age: 12Years +
All Genders
NCT04372615

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

Led by University of Utah · Updated on 2025-07-01

116

Participants Needed

39

Research Sites

339 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.

CONDITIONS

Official Title

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of NMDAR encephalitis confirmed by positive anti-NMDA receptor IgG antibody in cerebrospinal fluid
  • Subacute onset of mental status changes consistent with autoimmune encephalitis
  • Age 12 years or older at consent; participants under 18 must weigh at least 40 kilograms
  • Signed informed consent obtained before any study procedures
  • Sexually active participants with partners capable of becoming pregnant must use effective contraception during and after the study
  • Willing to avoid other immunomodulatory therapies for NMDAR encephalitis during the study
  • Received at least 3 days of high-dose corticosteroids and either IVIg or plasmapheresis within 90 days before randomization
  • Modified Rankin Score of 3 or higher at screening indicating moderate disability
  • Ability and willingness to attend study visits and complete the study
Not Eligible

You will not qualify if you...

  • Any condition that interferes with study treatment or safety, including recent herpes simplex virus encephalitis or known central nervous system demyelinating disease
  • Active or chronic serious infection
  • History of solid organ or cell transplantation
  • Enrollment in another investigational treatment study within 4 weeks or 5 half-lives prior to randomization
  • Pregnant or lactating individuals, or those planning pregnancy during study and 12 months after
  • Allergy or severe reaction to components of the investigational agent or biologic therapies
  • Receipt of certain immunosuppressive treatments or biologic B cell-depleting therapies within specified time frames prior to screening
  • Severe allergic history or anaphylaxis to multiple food or medicine products
  • Known primary immunodeficiency or conditions increasing infection risk
  • Active malignancy or history of malignancy active within last 10 years except certain treated skin or ovarian tumors
  • Abnormal blood counts or low immune cell levels at screening
  • Active hepatitis B or C infection
  • Use of live or attenuated vaccines within 4 weeks prior to study start
  • History of tuberculosis or signs of active TB without completed treatment
  • Active, clinically significant infection at randomization
  • History of alcohol or drug abuse affecting safety or compliance
  • Recurrence of NMDAR encephalitis within last 5 years or untreated disease longer than 3 months
  • Abnormal liver function tests or low platelet/hemoglobin counts requiring safety review
  • Untreated hepatitis C infection
  • Coexisting autoantibodies requiring safety review

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 39 locations

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

St. Joseph Hospital and Medical Center Barrow Neurological Institute

Phoenix, Arizona, United States, 85013

Actively Recruiting

3

Mayo Clinic in Arizona

Scottsdale, Arizona, United States, 85259

Actively Recruiting

4

Children's Hospital of Orange County

Orange, California, United States, 92868

Actively Recruiting

5

UC Irvine

Orange, California, United States, 92868

Actively Recruiting

6

UC Davis

Sacramento, California, United States, 95816

Actively Recruiting

7

Children's Hospital Colorado Main Campus

Aurora, Colorado, United States, 80045

Actively Recruiting

8

University of Colorado

Aurora, Colorado, United States, 80045

Actively Recruiting

9

Yale University

New Haven, Connecticut, United States, 06510

Actively Recruiting

10

Mayo Clinic Jacksonville

Jacksonville, Florida, United States, 32224

Actively Recruiting

11

University of Miami

Miami, Florida, United States, 33136

Actively Recruiting

12

Emory University

Atlanta, Georgia, United States, 30322

Actively Recruiting

13

Ann and Robert H. Lurie Childrens Hospital of Chicago

Chicago, Illinois, United States, 60611

Actively Recruiting

14

Northwestern University Feinberg School of Medicine

Chicago, Illinois, United States, 60611

Actively Recruiting

15

University of Iowa

Iowa City, Iowa, United States, 52242

Actively Recruiting

16

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

17

University of Michigan Health System

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

18

Mayo Clinic Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

19

Washington University in St. Louis School of Medicine

St Louis, Missouri, United States, 63110

Actively Recruiting

20

SUNY Downstate

Brooklyn, New York, United States, 11203

Actively Recruiting

21

Mount Sinai

New York, New York, United States, 10029

Actively Recruiting

22

Columbia University Medical Center

New York, New York, United States, 10033

Actively Recruiting

23

University of Rochester

Rochester, New York, United States, 14618

Actively Recruiting

24

SUNY Buffalo

Williamsville, New York, United States, 14221

Actively Recruiting

25

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States, 27101

Actively Recruiting

26

University of Cincinnati

Cincinnati, Ohio, United States, 45219

Actively Recruiting

27

Ohio State University

Columbus, Ohio, United States, 43210

Actively Recruiting

28

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

29

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15213

Actively Recruiting

30

Vanderbilt University

Nashville, Tennessee, United States, 37212

Actively Recruiting

31

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

32

Texas Children's Hospital

Houston, Texas, United States, 77030

Actively Recruiting

33

University of Utah

Salt Lake City, Utah, United States, 84108

Actively Recruiting

34

University of Virginia

Charlottesville, Virginia, United States, 22903

Actively Recruiting

35

University of Washington

Seattle, Washington, United States, 98195

Actively Recruiting

36

Erasmus Medical University Center

Rotterdam, Netherlands

Actively Recruiting

37

Erasmus University Rotterdam

Rotterdam, Netherlands

Actively Recruiting

38

Hospital Clínic Barcelona

Barcelona, Spain

Actively Recruiting

39

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona

Barcelona, Spain

Actively Recruiting

Loading map...

Research Team

S

Stacey L Clardy, MD, PhD

CONTACT

K

Ka-Ho Wong, MBA

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis | DecenTrialz